Coverage List

Stock

Ticker

Date Published

Market Price on Publication Date

Recommendation

Atlas Air Worldwide Holdings

AAWW US

17/03/2023

102.48

Removed from best ideas list in Deal Digest March 17, 2023

Black Knight

BKI US

17/03/2023

55.4

We see limited options for the parties to tackle all antirust issues.

InvoCare

IVC AU

16/03/2023

11.92

Based on InvoCare’s leading market share, the strength of the core business, historical valuation and precedent / peer multiples we believe that the Board might push for an increased bid.

Rothschild & Co

ROTH FP

14/03/2023

46.95

Considering the lengthy timeline, the current spread is tight. We assign low probability to a price bump.

Distell

DGH SJ

10/03/2023

17973

Removed from best ideas list in Deal Digest March 10, 2023

Atlas Air Worldwide Holdings

AAWW US

10/03/2023

99.93

Added to best ideas list in Deal Digest March 10, 2023

GK Software

GKS GR

10/03/2023

186

Added to best ideas list in Deal Digest March 10, 2023

Uni-Select

UNS CN

10/03/2023

46.77

The deal spread appears to be somewhat tight, given the lengthy deal review.

GK Software

GKS GR

09/03/2023

186.8

We don’t expect extended antitrust or FDI review and see deal close in June 2023.

Tegna

TGNA US

03/03/2023

17.04

Removed from best ideas list in Deal Digest March 3, 2023

TravelCenters of America

TA US

03/03/2023

84.57

We believe that an extended review is unlikely and the mid-2023 /3Q deal close guidance is realistic.

Newcrest Mining

NCM AU

01/03/2023

23.38

NCM is currently trading below the rejected offer. We would expect at least one improved offer from Newmont.

1Life Healthcare

ONEM US

24/02/2023

16.47

Removed from best ideas list in Deal Digest February 27, 2023

Cardiovascular Systems

CSII US

24/02/2023

19.71

We see a limited probability of an HSR second request. However, nowadays healthcare faces higher regulatory attention in the US. Hence, we would conclude that the current deal spread is tight.

Kape Technologies

KAPE LN

22/02/2023

293

While we don’t expect the Board to support the offer at the current valuation an increased offer appears to be unlikely. Unikmind would be close to the 70% minimum acceptance threshold with the support of ExpressVPN founders, and with their support they most likely have the majority required at the EGM (75% of votes cast) to delist KAPE. Unikmind might even succeed with its current shareholding of 54.8%.

Oak Street Health

OSH US

17/02/2023

35.38

Given the lengthy deal review and other pending deals, the spread appears to be fair. The spread will be driven by the outcome of pending deals in the industry.

Magnet Forensics

MAGT CN

17/02/2023

44.25

MAGT is currently trading at the bid price. One could speculate on a bump, as Thoma Bravo might need to lift its bid in case target shareholder opposition further mounts

NuVasive

NUVA US

15/02/2023

44.4

We would not rule out a second request and a longer than expected deal timeline.

Meltwater

MWTR NO

08/02/2023

17.81

We expect the offer to close in May 2023.

Evoqua Water Technologies

AQUA US

08/02/2023

50.25

The deal spread appears to be somewhat tight given the possible delay in case of an HSR second request.

IAA Inc

IAA US

02/02/2023

42.41

The key risk is the bidder shareholder vote. While we see a higher chance that the deal will receive the requisite shareholder approvals than not, independent proxy advisors’ view might be crucial.

Atlas Corp

ATCO US

02/02/2023

14.82

Based on the deal premium, our standalone value estimate, peer and precedent multiples, industry headwinds and the fact that no other shareholders joined opposing holders we believe that it is more likely that the deal will be approved at the AGM.

Horizon Therapeutics

HZNP US

27/01/2023

110.63

Added to best ideas list in Deal Digest Januar 27, 2023

Rovio

ROVIO FH

26/01/2023

7.16

Any deal would require the support of the controlling shareholder. There are no ongoing talks and the Rovio announcement sounds rather dismissive.

Horizon Therapeutics

HZNP US

26/01/2023

112.13

The deal spread appears to be somewhat wide thus we recommend a position long HZNP. We note the substantial downside.

ForgeRock

FORG US

24/01/2023

19.99

Overall, we believe regulators are more likely to approve the merger than not. Microsoft’s unquestionable market presence might cool down antitrust concerns.

Caverion

CAV1V FH

20/01/2023

7.97

We believe that Bain has to increase its offer to retain support of the Caverion Board.

National Instruments

NATI US

20/01/2023

53.87

Due to NATI’s strong takeover defenses, EMR can’t force a deal without Board consent. NATI might drag the strategic review and based on the CEO’s bullish comments, they might elect to remain a standalone company. We see limited upside to the current offer based on our ROIC and LBO calculations.

Tegna

TGNA US

18/01/2023

20.01

Added to best ideas list in Best Ideas Januar 18, 2023

Duck Creek Technologies

DCT US

13/01/2023

19

Given the valuation and the limited number of potential counterbidders, we see low probability for a counterbid. However, the short timeline and the limited deal risk might offer a favourable entry point for an improved offer.

CinCor Pharma

CINC US

13/01/2023

29.01

We believe the CVR could worth ~$2-2.3 per share. Based on that the current spread is unattractive.

Euronav

EURN BB

13/01/2023

13.44

Removed from best ideas list in Deal Digest January 13, 2023

Albireo

ALBO US

11/01/2023

43.85

The CVR does not appear to be cheap at $1.85 considering the potentially long timeline until payout.

Sierra Wireless

SW CN

02/01/2023

41.62

Removed from best ideas list in Deal Digest January 06, 2023

Nitro Software

NTO AU

06/01/2023

2.21

Nitro is trading slightly above the A$2.15 per share recommended bid. While we believe Potentia needs to raise its offer to win, it might not be able to outbid KKR’s Alludo.

Aerojet Rocketdyne

AJRD US

22/12/2022

55.6

We see much less incentive for LHX to foreclose any of AJRD’s customers, misuse missile related sensitive information or to decrease R&D investment in missile technology.

Maxar Technologies

MAXR US

22/12/2022

51.78

We believe regulatory risk is limited. We recommend a position long MAXR going into the go-shop period as a cheap bet on a low probability counterbid.

Chr Hansen

CHR DC

20/12/2022

501

The deal spread appears to be tight considering the long timeline and the regulatory risk.

Va-Q-tec

VQT GR

19/12/2022

25.4

We would be cautious to take a position long in VQT as there are key geographical and product overlap which might lead to antitrust scrutiny.

Apollo Endosurgery

APEN US

16/12/2022

9.91

The deal spread is tight; however, one might speculate on a counterbid as APEN’s attractive portfolio might attract other suitors. We don’t expect extended antitrust review.

Shaw Communications

SJR/B CN

13/12/2022

36.515

We believe that Shaw and Rogers have the upper hand in the Tribunal process.

Horizon Therapeutics

HZNP US

9/12/2022

97.22

We see some upside potential, as we expect that Horizon will receive an offer before the January 10 deadline, potentially around $110-120.

Univar Solutions

UNVR US

9/12/2022

33.4

We believe Brenntag could offer up to ~$40.50 for Univar, however it would need to issue a large number of new shares which would make the deal unattractive to the company despite the potential synergies.

Devro

DVO LN

8/12/2022

308.5

The merging parties anticipate a Q3 2023 deal close. This might indicate a high probability of an indepth antitrust review. Based on that, the deal spread appears to be somewhat tight.

Home Capital Group

HCG CB

2/12/2022

42.61

We believe the deal will receive the required regulatory approvals, however timing seems uncertain.

Origin Energy

ORG AU

1/12/2022

7.97

The possible upside on a firm deal announcement appears to be narrow, as regulatory concerns justify a wide spread, however we expect that after a lengthy review the ACCC approval will be granted.

Imago BioSciences

IMGO US

30/11/2022

35.7

We believe the deal spread is not attractive. The substantial downside and limited upside make us refrain from recommending a long IMGO.

Activision Blizzard

ATVI US

22/11/2022

82.15

Regulatory update

Vantage Towers

VTWR GR

22/11/2022

32.7

The domination agreement offers some upside (5-15%) which incentivizes minorities not to tender into the offer. This increases the probability of a domination agreement post offer.

IAA Inc

IAA US

17/11/2022

39.95

The main risks are the shareholder votes. Other IAA shareholders might oppose and put pressure on RBA and IAA boards to renegotiate

Atlantia

ATL IM

16/11/2022

22.93

Removed from best ideas list in Euro Best Ideas November 16, 2022

HomeServe

HSV LN

16/11/2022

1191

Removed from best ideas list in Euro Best Ideas November 16, 2022

Store Capital

STOR US

16/11/2022

31.7

The deal spread appears to be somewhat wide given the limited deal risk. We recommend a position long STOR.

Altra Industrial Motion

AIMC US

15/11/2022

58.43

We expect the deal to receive a second request in the US as the companies have several horizontal overlaps and are competing with each other in some niche markets.

Tegna

TGNA US

11/11/2022

18.99

Removed from best ideas list in Deal Digest November 11, 2022

Euronav

EURN BB

11/11/2022

18.08

Added to best ideas list in Deal Digest November 11, 2022

Euronav

EURN BB

10/11/2022

12.8

Given the high probability of a successful tender offer and limited deal risk, we believe the 2.5% deal spread is somewhat wide. Therefore, one may consider a position long deal spread with a view on a possibly shorter timeline.

ReadyTech

RDY AU

08/11/2022

4

We believe, PEP will come back with a sweetened offer, thus we would recommend a position long in RDY, especially as the spread is more than 10%. However, the downside could be around AUD3-3.1

Abiomed

ABMD US

07/11/2022

373.99

The CVR does not look attractive given the long expected timeline to trigger milestone payments.

Distell

DGH SJ

04/11/2022

17305

Added to best ideas list in Deal Digest November 4, 2022

Tower Semiconductor

TSEM US

04/11/2022

48.21

Removed from best ideas list in Deal Digest November 4, 2022

Sierra Wireless

SW CN

28/10/2022

40.33

Added to best ideas list in Deal Digest October 28, 2022

SeaSpine Holdings

SPNE US

27/10/2022

6.21

We see some risk regarding the shareholder approvals, however we are still optimistic that both shareholder groups
will vote for the merger.

Albertsons

ACI US

27/10/2022

20.36

The deal spread appears to be somewhat wide. However, political opposition, timeline and final consideration related uncertainties make us refrain from recommending a position long deal spread.

Sierra Wireless

SW CN

26/10/2022

40.54

We believe regulators will approve the deal without any remedies, as there are no horizontal overlaps and vertical issues are limited. Based on that, we would go long SWIR.

Interstrust

INTER NA

21/10/2022

19.94

Removed from best ideas list in Deal Digest October 21, 2022

Swedish Match

SWMA SS

21/10/2022

111.5

Removed from best ideas list in Deal Digest October 21, 2022

Aveva Group

AVV LN

20/10/2022

3147

Update on shareholder opposition - We believe target shareholder approval could be guaranteed with an offer of around GBp3300. We see Schneider sweetening its bid given that it is highly likely that publicly opposing shareholders have a blocking
stake

ForgeRock

FORG US

19/10/2022

22.54

Overall, we believe regulators will sign-off the deal given the fragmented nature of the IAM submarkets. We note the substantial downside.

Atlantia

ATL IM

14/10/2022

22.39

Added to best ideas list in Deal Digest October 14, 2022

Pushpay

PPH NZ

14/10/2022

1.15

A firm deal announcement could be made around NZD1.4, but we see it hard for BGH to win PPH Board’s support as it could be hard to negotiate a satisfactory offer for both parties.

Myovant

MYOV US

14/10/2022

25.1

Limited downside and high probability of an improved offer makes us recommend a long MYOV.

Poshmark

POSH US

11/10/2022

17.66

Deal risk is limited; thus the spread is tight. We expect the deal to close in mid-Q1 2023

1Life Healthcare

ONEM US

07/10/2022

16.98

Added to best ideas list in Deal Digest October 7, 2022

HomeServe

HSV LN

07/10/2022

1185

Added to best ideas list in Deal Digest October 7, 2022

DXC Technology

DXC US

07/10/2022

26.89

Assuming a 5% probability to an offer at $45 and 25% at $35 we would take a position long DXC below ~$27.

Capricorn Energy

CNE LN

07/10/2022

245.4

The main risks are the shareholder votes, thus we would retain from a position at this point.

Pendragon

PDG LN

04/10/2022

27.2

We believe that it would be difficult for the Board not to support Hedin’s 29p offer after the Board and other Top 5 shareholders were willing to engage with a third party in August at the same price. The Board might use the time until the PUSU deadline to try and find a better deal before granting its support to Hedin’s bid.

BTRS Holdings

BTRS US

04/10/2022

9.27

Deal risk is limited. We expect the deal to close in Q1 2023.

Pendal

PDL AU

30/09/2022

4.5

The market seems to be pessimistic about the deal. We would expect a deal close by the end of mid/late Q1.

Cano Health

CANO US

29/09/2022

8.84

We assign a high probability to a firm deal announcement. While activist shareholder and an analyst assume a $14 possible takeout price, with a conservative $12 takeout a riskreward still favors a position long CANO.

Atlas Air Worldwide Holdings

AAWW US

28/09/2022

95.88

The key risk is around debt financing, thus the deal spread is somewhat wide. We would refrain from a position long AAWW at this stage.

Tegna

TGNA US

23/09/2022

21.55

Update - We continue to consider the deal spread to be somewhat wide.

Avalara

AVLR US

23/09/2022

92.25

We would go long AVLR as we believe the majority of target shareholders will approve the deal, while we wouldn’t rule out a bump in the bid price if opposing shareholders gain enough support. However, we note that substantial (~30%) downside if the deal breaks on the vote.

Tyro Payments

TYR AU

16/09/2022

1.28

We expect that Tyro will receive a sweetened offer from either the consortium, another PE, or a strategic bidder.

GB Group

GBG LN

16/09/2022

5.94

Given the opportunistic timing of GTCR’s interest, there is a fair chance that talks fall apart. However, other PE firms might also turn up as GBG seems to be undervalued.

Signify Health

SGFY US

14/09/2022

29.07

The current 4.6% deal spread appears to be somewhat wide, assuming a deal close not earlier than mid-2023. We cannot rule out that vertical issues will be deeply scrutinized.

Brigham Minerals

MNRL US

13/09/2022

28.05

We believe that the 1Q2023 deal close guidance is manageable.

Link Net TBK

LINK IJ

09/09/2022

4750

Removed from best ideas list in Deal Digest September 9, 2022

Countryside Partnerships

CSP LN

09/09/2022

257.2

We see no major obstacles confronting the deal, as both shareholder and CMA approvals should be smooth. The deal spread appears to be wide, however we note that Vistry might be subject to a bid that could lead to a deal break.

Turquoise Hill Resources

TRQ CN

09/09/2022

41.23

Despite the materially improved bid from Rio Tinto, opposing shareholders have a good chance to derail the transaction.

RPS Group

RPS LN

05/09/2022

210

RPS is trading above terms on a counterbid/improved bid optionality, however we don’t see a counter bidder coming in, thus we would not take a position long RPS.

Link Net TBK

LINK IJ

02/09/2022

4750

Added to best ideas list in Deal Digest September 2, 2022

Drilling Co of 1972

DRLCO DC

02/09/2022

369.4

Removed from best ideas list in Deal Digest September 2, 2022

AVEVA

AVV LN

02/09/2022

2810

We would recommend taking a position long AVEVA as we expect a firm deal in the range of GBp2950-3150.

Micro Focus International

MCRO LN

30/08/2022

519

The deal is expected to close in 1Q2023 due to the numerous regulatory approvals required.

Nearmap

NEA AU

26/08/2022

2.1

A counterbid from another private equity appears to be unlikely, however cannot be ruled out completely.

Recipe Unlimited

RECP CN

26/08/2022

19.85

One may consider a position long RECP going into deal announcement

Darktrace

DARK LN

22/08/2022

5.26

We believe there is good chance for an agreed firm deal with Thoma Bravo. The target might squeeze out an offer above 700p given the attractive valuation and possible counterbid interest.

OZ Minerals

OZL AU

18/08/2022

25.84

While deal rationale appears to be strong, the gap between parties’ valuation might be too large to overcome.

Atlantia

ATL IM

16/08/2022

22.84

Removed from best ideas list in Euro Best Ideas August 16, 2022

Meggitt

MGGT LN

16/08/2022

792.8

Removed from best ideas list in Euro Best Ideas August 16, 2022

ChemoCentryx

CCXI US

16/08/2022

50.89

Based on the minor overlap in AAV treatment, regulatory scrutiny is unlikely to arise.

Global Blood Therapeutics

GBT US

15/08/2022

66.75

An HSR re-filing might not be ruled out, however a second request appears to be unlikely based on the overlap and the competitive dynamics of the SCD space. Product related developments are not carved out of MAE, however no significant events are expected before deal close. 

iRobot

IRBT US

10/08/2022

59.5

We would not take a position at this time given the regulatory risks, long deal timeline and IRBT’s challenges.

Ping Identity Holding Corp

PING US

09/08/2022

28.01

Deal risk is limited. We don’t see upside to the offer price thus chances of a counterbid are low.

Quilter

QLT LN

09/08/2022

119.5

While it is hard to see whether a firm deal will materialize, we see the deal rationale, and would expect an offer price between GBp145-160.

Infomedia

IFM AU

03/08/2022

1.59

We expect a firm deal announcement with final offer price around AUD1.75-1.85.

Serica Energy

SQZ LN

02/08/2022

355.5

We don’t see the deal being accretive for bidder shareholders at current terms. Even assuming significant synergies does not change the math.

Link Net TBK

LINK IJ

29/07/2022

4650

Removed from best ideas list in Deal Digest July 29, 2022

1Life Healthcare

ONEM US

29/07/2022

16.97

We believe that the deal might get a second request given the global scrutiny surrounding Big Tech, however it is likely to be approved given the lack of significant antitrust concerns

Infrastructure and Energy Alternatives

IEA US

29/07/2022

14.14

We don’t expect an extended antitrust review given the competitive and fragmented market. As per our valuation, counterbid is also possible.

Ironsource

IS US

28/07/2022

3.87

We see the merger as a good opportunity both for Ironsource and Unity shareholders, with some extra risk for Unity, as the leverage gained on a ad-tech asset might be badly timed.

Meridian Bioscience

VIVO US

25/07/2022

32.48

The deal spread reflects the DOJ investigation-related uncertainty.

Epizyme

EPZM US

21/07/2022

1.48

We see no major risk for the deal to finalize, but we are cautious about whether the shareholders will receive any CVR, although one may consider buying an almost free option for the possible CVR payouts.

Resolute Forest Products

RFP US

19/07/2022

20.22

We believe the deal will be approved with remedies after an extended Canadian antitrust review. The likelihood of the CVR payout seems highly uncertain.

Intertrust NV

INTER NA

15/07/2022

19.04

Added to best ideas list in Deal Digest July 15, 2022

Vivo Energy

VVO LN

15/07/2022

152.8

Removed from best ideas list in Deal Digest July 15, 2022

Valora Holding

VALN SW

14/07/2022

259

The deal poses no major risk, therefore probability of close is high at offer terms. A counterbid cannot be ruled out, however we see it as a wild card scenario.

Autogrill Spa

AGL IM

14/07/2022

6.3

The transfer of Edizione’s 50.3% stake is currently expected to close in Q1 2023, subject to regulatory approvals, while the transaction inclusive of mandatory takeover offer settlement is expected to be completed by Q2 2023.

Twitter

TWTR US

12/07/2022

32.65

We believe that Musk’s arguments are not strong enough to justify deal termination. While Twitter has good chance to enforce specific performance, the court might prefer the parties agreeing in a cut price deal or awarding damages instead of forcing an unwilling buyer to acquire Twitter.

LifeWorks

LWRK CN

08/07/2022

31.11

The deal spread appears to be somewhat wide however timing of the deal and dividend differential changes make a position difficult to evaluate. Low deal risk and significant downside makes us cautious.

ContourGlobal

GLO LN

05/07/2022

2.525

One might consider going long GLO as deal risk seems to be limited. However, we note the substantial downside.

Radius Health

RDUS US

05/07/2022

10.48

We see some risk regarding the CVR payment condition and the 50+% tender offer condition too, not ruling out that the bidder consortium will raise the offer.

Swedish Match

SWMA SS

01/07/2022

104.55

Added to best ideas list in Deal Digest July 1, 2022

Drilling Co of 1972

DRLCO DC

01/07/2022

282.6

Added to best ideas list in Deal Digest July 1, 2022

Zendesk

ZEN US

01/07/2022

74

The mix of ZEN financing and the involvement of private debt from cash-rich shadow lenders makes us confident that the financing of the takeover will be less exposed to any debt market turmoil

Emis Group

EMIS LN

29/06/2022

1864

The deal spread does not appear to be attractive considering the estimated timeline, the overlaps between the companies, EMIS’ high market share in certain segments and involvement of sensitive healthcare data.

Shaftesbury

SHB LN

29/06/2022

546.5

We believe that the key risk to the deal is the SHB shareholder vote. As a standalone company, we see SHB shares trading around 600p, which makes an SHB shareholder approval unlikely.

Go-Ahead Group

GOG LN

29/06/2022

15.92

We believe there is good chance for a higher offer either from Kelsian or other parties.

Drilling Co of 1972

DRLCO DC

24/06/2022

311

Removed from best ideas list in Deal Digest June 24, 2022

Duke Realty Corp

DRE US

21/06/2022

51.44

We see limited deal risk around the shareholder votes as the deal rationale appears to be strong.

Turning Point Therapeutics

TPTX US

21/06/2022

74.46

The deal spread appears to be somewhat wide thus, we recommend a long position TPTX. We note the substantial downside around $30/TPTX.

Yancoal Australia

YAL AU

16/06/2022

5.45

We expect Yankuang to sweeten its offer significantly to earn board and shareholder support.

Biffa

BIFF LN

14/06/2022

4.08

We believe there is good chance for a firm deal either at 445p or more. Based on our valuation, there is upside to the deal price thus target shareholders might be able to squeeze out a higher offer if an agreed firm deal materializes.

Accell Group

ACCEL NA

10/06/2022

58

Removed from best ideas list in Deal Digest June 10, 2022

Yamana Gold

YRI CN

10/06/2022

6.84

The deal spread appears to be somewhat wide however shareholder support might be in jeopardy based on the GFI share price reaction.

Capricorn Energy

CNE LN

08/06/2022

207.4

We believe the key risks are the shareholder votes, especially for the target as the promised synergies and strategic rational might not offset the lack of meaningful deal premium.

FirstGroup

FGP LN

03/06/2022

1.37

We believe the bidder might need to further increase its bid to secure board support.

VMWare

VMW US

01/06/2022

129

The deal spread does not appear to be attractive at this point given the long deal timeline.

ManTech International

MANT US

31/05/2022

95.4

Deal risk is limited. We wouldn’t expect a counterbid as there might have been a sale process before the agreement with Carlyle.

Siemens Gamesa

SGRE SM

31/05/2022

17.85

Given the actual market conditions and the outlook for Gamesa, we do not expect a bump in the offer price as the substantial downside for the standalone company increases the probability of the shareholders tendering into the offer

Cerner

CERN US

27/05/2022

94.68

Removed from best ideas list in Deal Digest May 27, 2022

HomeServe

HSV LN

27/05/2022

1163

The deal spread appears to be somewhat wide given the upside optionality to the deal timeline and the limited deal risk. We note the significant downside.

Swedish Match

SWMA SS

24/05/2022

101.85

We expect the deal to go through as we see no major competition issues. We also see some upside, as PM could raise the offer price under SWMA shareholder pressure.

Black Knight

BKI US

23/05/2022

71.81

The current spread reflects the lengthy deal timeline and the probability of the deal falling apart. We
also note that there is no litigation obligation and divestiture obligation is limited to BKI assets.

Tower Semiconductor

TSEM US

20/05/2022

45.69

Added to best ideas list in Deal Digest May 20, 2022

Tegna

TGNA US

20/05/2022

20.99

Added to best ideas list in Deal Digest May 20, 2022

Columbia Care

CCHW CN

20/05/2022

2.69

Added to best ideas list in Deal Digest May 20, 2022

Silicon Motion Technology Corp

SIMO US

20/05/2022

90.67

We would not take a position long SIMO at this point given the lengthy timeline. The Chinese approval poses substantial risk to the deal, in our view.

Alliance Aviation

AQZ AU

19/05/2022

4.01

We believe that the antitrust risk is high. The ACCC’s comments after its 3-year review of Qantas’ original minority stake purchase, the limited number of competitors in the target’s key markets and Alliance’s collaboration agreement with Virgin make us cautious.

Zynga

ZNGA US

20/05/2022

8.18

Removed from best ideas list in Americas Best Ideas May 16, 2022

Biohaven

BHVN US

16/05/2022

141

Deal risks appear to be limited. We note that product related adverse events are not carved out of MAE.

Twitter

TWTR US

11/05/2022

47.26

The deal spread appears to be somewhat wide. Assuming a $30 downside and an early August deal close deal closing probability is around 72%.

Shaw Communications

SJR/B CN

09/05/2022

34.87

The key question is whether Rogers believes that deal benefits (larger cable business, 5G spectrum) outweigh the competitive threat posed by a stronger Quebecor. We are less convinced, that Rogers would vigorously pursue the deal in case Quebecor is not approved as a buyer before the extended Outside date, July 31.

Activision

ATVI US

06/05/2022

77.84

Added to best ideas list in Deal Digest May 6, 2022

Accell Group

ACCEL NA

06/05/2022

57

Added to best ideas list in Deal Digest May 6, 2022

Atlantia

ATL IM

06/05/2022

22.85

Added to best ideas list in Deal Digest May 6, 2022

Meggitt

MGGT LN

06/05/2022

778

Added to best ideas list in Deal Digest May 6, 2022

Link

LNK AU

06/05/2022

4.96

We would take a long position on Link as we think the Woodford issue will not materialize in any public finding from the FCA in the upcoming months, but we would wait the next merger update to assess the possible timeline delay to mitigate the downside risk.

Ubisoft Entertainment

UBI FP

04/05/2022

43.01

We believe Ubisoft is likely to receive indicative proposals from either PEs or strategic buyers.

Datto

MSP US

04/05/2022

34.61

The deal spread appears to be wide given the limited deal risk. The number of competitors makes a rigorous antitrust review unlikely. Further, in case of an extended review, the divestiture obligation makes a successful deal close likely.

South Jersey Industries

SJI US

29/04/2022

34.42

The long timeframe and potential regulatory risks do not justify a position long SJI for now. However, the deal will ultimately be approved in our view, after a thorough review.

Autogrill Spa

AGL IM

27/04/2022

6.9

The deal has a good chance of approval in our view, given the complementary nature (both in terms of geographic and product category exposure) of the businesses and factors that highlight the competitiveness of the travel retail market and the bidding for concessions:

Ramsay Health

RHC AU

25/04/2022

84.27

We expect a firm deal to be struck most likely under these conditions, however we cannot rule out a slightly higher offer, as Ramsay’s books may forecast a brighter than expected future as covid restrictions are almost completely gone

Citrix

CTXS US

22/04/2022

101.5

Added to best ideas list in Deal Digest April 22, 2022

Ferro

FOE US

22/04/2022

22.01

Removed from best ideas list in Deal Digest April 22, 2022

Twitter

TWTR US

22/04/2022

47.08

Given Musk’s commitment to the deal and the potential upside to the current proposal one may consider a position long TWTR. We note the substantial downside which could be even lower once Musk becomes a seller of TWTR shares.

Atlantia

ATL IM

20/04/2022

22.79

A counter bid or a higher offer appear unlikely. The deal could close in 3Q2022.

Intersect ENT

XENT US

14/04/2022

27.96

Removed from best ideas list in Deal Digest April 14, 2022

Euronav

EURN BB

14/04/2022

11.82

Update - We are altering our view laid out in our April 13 initiation report. As a successful deal close without CMB’s support is unlikely, there is a risk that parties reconsider their intention to combine or in case they push forward with a firm deal, it might fail on shareholder opposition. We no longer recommend setting up the deal spread.

Nielsen Holdings

NLSN US

14/04/2022

27.24

Despite WindAcre’s opposition, bidders have a good shot to succeed with takeover offer, in our view. The key question is whether WindAcre manages to convince enough Nielsen shareholders to oppose the transaction.

Euronav

EURN BB

13/04/2022

11.82

Given the high probability of a firm deal and a tighter spread post announcement, one may consider a long position on the deal spread.

Neenah

NP US

08/04/2022

38.23

Regulatory risk is limited. Shareholder opposition might arise as the value of SWM’s all-share offer is lower than NP’s current share price.

Pendal

PDL AU

08/04/2022

5.27

We expect the Pendal Board to reject the offer under these terms, as it is opportunistic and undervalues PDL. As the Fund Management sector needs to consolidate, we expect PPT to sweeten its bid.

Spirit Airlines

SAVE US

07/04/2022

26.28

We see the SAVE/ULCC merger more viable from a regulatory perspective than a SAVE/JBLU combination. The SAVE board, however might find it hard to turn down JBLU’s offer.

Columbia Care

CCHW CN

05/04/2022

3.59

The deal spread appears to be wide given the limited downside, therefore would recommend a position long the deal spread.

Western Areas

WSA AU

01/04/2022

3.65

We think that the bullish outlook of nickel and the pressure put on IGO by the Indepent Expert’s report and WSA shareholders will result in a sweetend offer price. Downside risk seems limited based on WSA valuation.

LHC Group

LHCG US

31/03/2022

168

We would not be surprised if the deal received a second request given UNH’s size and its acquisition of Landmark Health.

Anaplan

PLAN US

29/03/2022

65.13

Deal risk is limited. We attach low chance to a counterbid given the fair premium and the support of activist shareholders.

Neles

NELES FH

25/03/2022

9.11

Removed from best ideas list in Deal Digest March 25, 2022

Pearson

PSON LN

25/03/2022

767

A 30%-50% probability of an improved and agreed offer around 900p-950p makes us believe that the current PSON share price offers a favorable risk/reward to enter a position long PSON below ~770p.

Turquoise Hill Resources

TRQ CN

23/03/2022

38.24

We believe Rio Tinto needs to improve its offer materially to succeed.

Mediaset Espana

TL5 SM

22/03/2022

4.59

We expect MES shareholders to reject the offer and MFE to return with a sweetened bid to pursue its European expansion plans. TL5 downside appears to be limited at these levels.

Mandiant

MNDT US

18/03/2022

22.15

We would take a position long MNDT at current stage.

Avast

AVST LN

18/03/2022

568

Our main concern is that remedies might be difficult to structure.

CareTech

CTH LN

11/03/2022

670

We see likely that a firm deal announcement will happen before the April 4 deadline with an offer price around GBp725-775.

Houghton Mifflin Harcourt

HMHC US

08/03/2022

20.88

We believe the limited downside, the short timeframe, and the substantial upside offer a favorable risk-reward for a position long HMHC.

Nuance

NUAN US

04/03/2022

55.99

Removed from best ideas list in Deal Digest March 4, 2022

Z Energy

ZEL NZ

04/03/2022

3.68

Removed from best ideas list in Deal Digest March 4, 2022

Oxford Instruments

OXIG LN

04/03/2022

23

We believe a firm deal has strong strategic rationale, as the product portfolios are rather complementary. We see no upside to the offer price; however downside is significant in a no-deal situation. The Ukrainian war might also affect the chances of a firm deal.

AGL Energy

AGL AU

04/03/2022

7.42

We expect the bidder to come back with an improved offer. We expect a lengthy regulatory review in case a firm deal is reached.

Tegna

TGNA US

02/03/2022

22.84

The deal spread appears to be somewhat wide however the lengthy deal timeline makes us cautious recommending a position long TGNA this time.

Z Energy

ZEL NZ

02/03/2022

3.64

The key risk is timing, as the NZCC in our view is likely to require upfront divestiture of the Gull business.

MoneyGram International

MGI US

25/02/2022

10.75

Deal risk appears to be limited. We recommend a position long MGI going into the go-shop period, as the current deal spread offers a cheap bet on a low probability counterbid.

Tower Semiconductor

TSEM US

23/02/2022

46.87

We expect the deal to receive regulatory approvals given the complementary nature and the limited market share in the foundry business. The key question appears to be timing of the SAMR decision.

US Ecology

ECOL US

22/02/2022

47.2

Considering a mid 2Q 2022 deal close the deal spread is at the upper end of a plain vanilla transaction. However we cannot completely rule out a rigorous review and some delay in the deal timeline. This makes us refrain from recommending a position long ECOL at current stage. Ultimately we see the
deal being closed.

John Menzies

MNZS LN

18/02/2022

5.83

We believe there is a good chance for a firm deal either at 605p or more

BioDelivery Sciences

BDSI US

16/02/2022

5.56

The deal spread does not appear to be attractive. An extended review appears unlikely, therefore the deal could close in line with the 1Q guidance.

Link Net TBK

LINK IJ

15/02/2022

4330

Added to best ideas list in APAC Best Ideas February 15, 2022

Zynga

ZNGA US

15/02/2022

9.05

Added to best ideas list in Americas Best Ideas February 15, 2022

Cerner

CERN US

15/02/2022

92.03

Added to best ideas list in Americas Best Ideas February 15, 2022

Vivo Energy

VVO LN

15/02/2022

133

Added to best ideas list in Euro Best Ideas February 15, 2022

VIB Vermoegen

VIH1 GR

11/02/2022

52.8

We don’t see significant chance for a higher offer from DIC. The effective minimum acceptance condition of 18.5% is quite low and waivable. VIB appears to be overvalued compared to its peers and DIC faces constraints to improve its bid (leverage, FFO accretion).

Cedar Fair

FUN US

11/02/2022

59.71

Reaching a firm deal might be difficult and a hostile offer seems unlikely given FUN’s strong takeover defenses. We note the substantial upside above $75. Downside in a no deal situation is around $50.

Spirit Airlines

SAVE US

11/02/2022

27.3

The merger is likely to face antitrust scrutiny in the US. The merging parties compete in several overlapping city-pairs, where they would have ability and incentive to raise prices after the combination.

Citrix

CTXS US

04/02/2022

102.9

Deal risks appear to be limited, however we find the current spread unattractive.

Link Net TBK

LINK IJ

02/02/2022

4430

We believe the transaction will receive the necessary approvals in the expected timeline, offering attractive upside potential.

Neo Lithium

NLC CN

28/02/2022

6.49

Removed from best ideas list in Best Ideas January 28, 2022

 

 

 

 

 

Please note that every week Chain Bridge publishes a list of their top ideas (Deal Digest).  As noted in the table above, companies are added or removed to that list to communicate conviction level.

 

All materials published by Chain Bridge Research, f/k/a Independent European Research, LLC, are intended for use only by professional, institutional, buy-side investors. Use by the general investing public is prohibited. The information and analysis contained in these publications are copyrighted and may not be duplicated or redistributed for any reason. Chain Bridge Research reserves the right to refuse any subscription request based upon the above criteria. Companies and individuals residing in Hungary, and affiliates of firms based in Hungary are prohibited from subscribing to the services of Chain Bridge Research.

Neither the information, nor any opinion expressed, in a Chain Bridge report constitutes a solicitation by Chain Bridge for the purchase or the sale of securities. Chain Bridge reports do not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual investors. The information set forth in the reports was obtained from publicly available sources that we believe to be reliable. While due care is taken by Chain Bridge in compiling the data and in forming its opinions, Chain Bridge gives no warranty, express or implied, and it does not guarantee the accuracy or completeness of the information provided.

The reports published by Chain Bridge intend to provide professional, institutional, buy-side investors with a view regarding the various risks and critical factors impacting the completion of certain mergers and acquisitions. Therefore, the opinions expressed do not fit with traditional buy, sell, and hold ratings.